About Pricing FAQs Blog

Loading clinical trials...

Clareo Health Find Clinical Trials →

© 2026 Clareo Health. All rights reserved.

Lung Cancer Clinical Trials in Michigan | 304 Studies | Clareo Health

Clinical Trials Lung CancerMichigan

Lung Cancer Clinical Trials in Michigan

Find 304 clinical trials for lung cancer near Michigan. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Michigan

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 141-160 of 304 trials

ACTIVE_NOT_RECRUITINGPHASE162 miles

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Pancreatic CancerBreast CancerGastric Cancer+13 more

NGM Biopharmaceuticals, Inc130 participantsStarted Mar 2022

Gilbert, Arizona, United States • Los Angeles, California, United States • Sarasota, Florida, United States +6 more locations

ACTIVE_NOT_RECRUITINGPHASE1/PHASE262 miles

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

MesotheliomaGlioblastomaRenal Cell Carcinoma+12 more

NGM Biopharmaceuticals, Inc179 participantsStarted Jun 2021

Los Angeles, California, United States • Newport Beach, California, United States • Santa Monica, California, United States +24 more locations

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RECRUITINGPHASE362 miles

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

NCT06095583

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death protein-1 (PD-1). Neither drug is approved for treatment of This combination regimen is investigational in limited stage-small cell lung cancer in any country.

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Shanghai Junshi Bioscience Co., Ltd.756 participantsStarted Nov 2023

Goodyear, Arizona, United States • Tucson, Arizona, United States • Hot Springs, Arkansas, United States +153 more locations

COMPLETEDPHASE1/PHASE283 miles

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

NCT01970865

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

Pfizer364 participantsStarted Jan 2014

Fayetteville, Arkansas, United States • Rogers, Arkansas, United States • Orange, California, United States +74 more locations

COMPLETEDPHASE1/PHASE283 miles

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

NCT01712217

The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer(NSCLC)

Astex Pharmaceuticals, Inc.220 participantsStarted Oct 2012

Scottsdale, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +62 more locations

TERMINATEDPHASE1/PHASE283 miles

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391

A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. The study consists of three portions: 1) Phase 1 Dose Escalation and Food Effect Sub-study, and 2) Phase 1 dose expansion and 3) Phase 2 efficacy evaluation.

Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more

Turning Point Therapeutics, Inc.41 participantsStarted Dec 2019

La Jolla, California, United States • Orange, California, United States • Aurora, Colorado, United States +18 more locations

UNKNOWN86 miles

Lung EpiCheck Biomarkers Development Study

NCT06245876

This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.

Nucleix Ltd.6,000 participantsStarted May 2022

Miami, Florida, United States • Panama City, Florida, United States • Shreveport, Louisiana, United States +7 more locations

COMPLETEDPHASE2102 miles

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

NCT03473925

The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC).

Solid TumorsNon-small Cell Lung CancerCastration Resistant Prostate Cancer+1 more

Merck Sharp & Dohme LLC107 participantsStarted Apr 2018

Scottsdale, Arizona, United States • Sarasota, Florida, United States • Baltimore, Maryland, United States +11 more locations

TERMINATEDPHASE1/PHASE2155 miles

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NCT00807612

This is a global, multicenter, 2-part, open-label phase 1b and single-arm phase 2 study designed to evaluate the safety and efficacy of AMG 479 in combination with paclitaxel and carboplatin for the first-line treatment of advanced squamous non-small cell lung carcinoma.

Advanced Squamous Non-Small Cell Lung Cancer

NantCell, Inc.15 participantsStarted Jan 2009

Fayetteville, Arkansas, United States • Fayetteville, Arkansas, United States • Fort Wayne, Indiana, United States +22 more locations

COMPLETEDPHASE2192 miles

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

NCT02855125

This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in patients with advanced or metastatic NSCLC. The study will be conducted internationally in 2 regions: Asian \[Japan\] and Western \[Europe and US\]. Patients will be randomized into TAS-114/S-1 arm versus S-1 control arm in a 1:1 ratio.

Advanced or Metastatic Non-small Cell Lung Cancer

Taiho Oncology, Inc.128 participantsStarted Aug 2016

Loma Linda, California, United States • Gainesville, Florida, United States • Cleveland, Ohio, United States +27 more locations

COMPLETEDPHASE2236 miles

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

NCT02337530

The purpose of this study is to find out what effects a new drug, selumetinib, has on lung cancer when receiving standard chemotherapy with pemetrexed and platinum-based chemotherapy.

Non-Small Cell Lung Cancer

Canadian Cancer Trials Group62 participantsStarted May 2015

Calgary, Alberta, Canada • Edmonton, Alberta, Canada • Abbotsford, British Columbia, Canada +9 more locations

TERMINATEDPHASE3238 miles

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587

The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC who progressed after sequential or concurrent chemotherapy and immune checkpoint inhibitor given in first or second-line treatment. The main questions were to compare the survival, the tolerance to treatment and the quality of life of patients between the two arms of treatment (OSE2101 versus standard chemotherapy)

Non Small Cell Lung Cancer

OSE Immunotherapeutics219 participantsStarted Feb 2016

Burbank, California, United States • Washington D.C., District of Columbia, United States • Boca Raton, Florida, United States +75 more locations

COMPLETEDPHASE1287 miles

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866

This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

AIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more

National Cancer Institute (NCI)58 participantsStarted Apr 2016

Birmingham, Alabama, United States • San Francisco, California, United States • San Francisco, California, United States +9 more locations

COMPLETEDPHASE2290 miles

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

NCT02200757

The purpose of this study is to evaluate the efficacy and safety of aldoxorubicin compared to topotecan in subjects with metastatic small cell lung cancer.

Metastatic Small Cell Lung Cancer

ImmunityBio, Inc.135 participantsStarted Apr 2015

Los Angeles, California, United States • Pasadena, California, United States • Fleming Island, Florida, United States +26 more locations

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2307 miles

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

NCT04216316

This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung cancer that has spared to other placed in the body (advanced). Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving berzosertib together with carboplatin, gemcitabine, and pembrolizumab may work better in treating patients with squamous cell non-small cell lung cancer compared to carboplatin, gemcitabine, and pembrolizumab alone.

Lung Non-Small Cell Squamous CarcinomaStage IV Lung Cancer AJCC v8

National Cancer Institute (NCI)12 participantsStarted Apr 2021

Los Angeles, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +31 more locations

TERMINATEDPHASE4399 miles

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

NCT05583188

A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for standard of care neoadjuvant use of checkpoint inhibitor (nivolumab) treatment plus platinum doublet chemotherapy.

Galvanize Therapeutics, Inc.5 participantsStarted Feb 2023

Rochester, Minnesota, United States • Philadelphia, Pennsylvania, United States • Philadelphia, Pennsylvania, United States

ACTIVE_NOT_RECRUITINGPHASE1439 miles

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

NCT04432857

This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase followed by an expansion phase. All enrolled patients will be treated with AN0025 and Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of AN0025 and in each cohort.

Triple-negative Breast CancerNSCLC, Squamous or Non-SquamousUrothelial Carcinoma of the Bladder+2 more

Adlai Nortye Biopharma Co., Ltd.63 participantsStarted Aug 2020

St Louis, Missouri, United States • Houston, Texas, United States • Salt Lake City, Utah, United States +3 more locations

TERMINATEDPHASE1509 miles

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric Cancer+9 more

ADC Therapeutics S.A.78 participantsStarted Nov 2018

Palo Alto, California, United States • New Haven, Connecticut, United States • Portland, Oregon, United States +6 more locations

COMPLETED560 miles

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

NCT03892096

Accrue samples for the further development and clinical validation of a blood-based cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay as a potential biomarker for early non-response to therapy in stage IV non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BC).

Metastatic Non-Small Cell Lung CarcinomaMetastatic Colorectal CancerMetastatic Breast Cancer

Cadex Genomics130 participantsStarted Mar 2019

Little Rock, Arkansas, United States • Sunnyvale, California, United States • Denver, Colorado, United States +9 more locations

TERMINATEDPHASE11111 miles

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

NCT04822298

This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).

Non-small Cell Lung CancerNSCLC

Amgen3 participantsStarted Aug 2021

Houston, Texas, United States • Camperdown, New South Wales, Australia • Salzburg, Austria +1 more locations

PreviousPage 8 of 16Next

Other Conditions in Michigan

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma